Novo Nordisk investors should be aware that on January 24, 2025, a class action lawsuit was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk”) (NYSE: NVO) securities between November 2, 2022, and December 19, 2024, inclusive (the “Class Period”). This lawsuit seeks to recover damages caused by Defendants’ alleged violations of federal securities laws.
What Can You Do if You Purchased or Acquired Novo Nordisk Securities During the Class Period?
If you purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024 and suffered losses, you may be eligible to participate in this class action lawsuit.
Get More Information or Speak with an Attorney
To learn more about the class action lawsuit or to find out if you’re eligible to participate, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], for a free, no-obligation evaluation of your potential claims.
Alternatively, you can email [email protected] or complete our online confidential Securities Class Action Questionnaire, and you will be contacted by a legal professional.
Class Action Allegations
The Novo Nordisk class action alleges that Defendants misled investors about the Phase 3 CagriSema obesity study, “REDEFINE-1.” The lawsuit claims that critical details about the flexible dosing protocol in the study were not disclosed to investors, including the fact that patients could adjust their doses during the trial. As a result, Novo Nordisk’s stock traded at artificially inflated prices during the Class Period.
On December 20, 2024, Novo revealed disappointing results from the REDEFINE-1 trial, revealing a 22.7% average weight loss instead of the anticipated 25% average weight loss for obesity patients treated with CagriSema in the study.
Following this announcement, Novo Nordisk’s stock price fell sharply by 17.83%, from $103.44 per share on December 19, 2024 to $85.00 per share on December 20, 2024.
To view the complaint, click Novo Nordisk class action complaint.
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Our firm has recovered over $10 billion for institutional and individual investors.
All legal consultations are completely free and with no obligation to pursue a case. Legal services are provided on a contingency-fee basis, meaning you are not responsible for any fees or litigation expenses.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103